Suppr超能文献

自体条件血浆与类固醇注射治疗肱骨外上髁炎的随机研究。

A randomized study of autologous conditioned plasma and steroid injections in the treatment of lateral epicondylitis.

作者信息

Lebiedziński Radosław, Synder Marek, Buchcic Piotr, Polguj Michał, Grzegorzewski Andrzej, Sibiński Marcin

机构信息

Clinic of Orthopaedics and Paediatric Orthopaedics Medical University of Łódź, Pomorska 251, 92-213, Łodź, Poland.

Department of Angiology, Chair of Anatomy, Medical University of Łódź, 91-002, Łódź, Poland.

出版信息

Int Orthop. 2015 Nov;39(11):2199-203. doi: 10.1007/s00264-015-2861-0. Epub 2015 Jul 30.

Abstract

PURPOSE

Chronic tendinopathy of lateral epicondyle of the humerus, commonly known as "tennis elbow" is one of the most frequent tendinopathies caused by recurrent overload of the muscle origins. The aim of the study was to assess the effectiveness of treating lateral epicondylitis (LE) with autologous conditioned plasma (ACP) and betamethasone injections, and to compare these methods over the course of a one year follow-up.

METHODS

Patients were randomly placed into one of into two groups: 53 were treated with ACP, and 46 with 1 ml betamethasone injections and 2 ml of 1 % lignocaine. Both those groups were comparable in terms of initial DASH score.

RESULTS

After six weeks and six months, the mean DASH score was significantly better in the betamethasone group, but was better in ACP group after one year. Full recovery (patients with no symptoms) at all time points was more common in the betamethasone group. A comparison of grouped DASH scores revealed more very good and good results in the ACP group after one year. More patients had pain symptoms related to injection in the ACP group than the betamethasone group.

CONCLUSIONS

ACP therapy of LE allows better results to be obtained at 12 months. Betamethasone injections give more rapid improvement, but the therapeutic effect is longer lasting in the ACP group.

摘要

目的

肱骨外上髁慢性肌腱病,俗称“网球肘”,是肌肉起点反复超负荷引起的最常见的肌腱病之一。本研究的目的是评估自体浓缩血浆(ACP)和倍他米松注射治疗外侧上髁炎(LE)的有效性,并在一年的随访过程中比较这些方法。

方法

患者被随机分为两组:53例接受ACP治疗,46例接受1 ml倍他米松注射和2 ml 1%利多卡因治疗。两组的初始DASH评分具有可比性。

结果

六周和六个月后,倍他米松组的平均DASH评分明显更好,但一年后ACP组更好。在所有时间点完全恢复(无症状患者)在倍他米松组更常见。分组DASH评分比较显示,一年后ACP组有更多非常好和良好的结果。与倍他米松组相比,ACP组有更多患者出现与注射相关的疼痛症状。

结论

LE的ACP治疗在12个月时能取得更好的效果。倍他米松注射改善更快,但ACP组的治疗效果持续时间更长。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验